


Please amend the subject application as follows:

AMENDMENTS TO THE CLAIMS

The listing of the claims will replace all prior versions, and listings, of the claims in the application.

Listing of the Claims

1. (Currently Amended) A compound of formula (I)



Formula (I)

wherein:

X is O, ~~NH~~, or ~~N-CN~~;

n is the integer 0, ~~1~~, ~~2~~, or ~~3~~;

m is the integer 0, 1, 2, or 3;

R^1 , R^2 , R^3 , R^4 independently represent ~~cyano, halogen, hydrogen, hydroxyl, C1-C5 alkyl, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkenyloxy, trifluoromethoxy, or cycloalkyloxy~~ or R^1 and R^2 together as well as R^2 and R^3 together or R^3 and R^4 together may form with the phenyl ring to which they are attached, a five, six or seven membered ring containing one or two oxygen atoms which are separated by at least one carbon atom;

R^5 represents hydrogen, C1-C5 alkyl, ~~C2-C5 alkenyl, cycloalkyl, cycloalkyl-C1-C5 alkyl, $(CH_2)_m$ -O-C1-C5 alkyl, $(CH_2)_m$ -COOH, $-(CH_2)_m$ -CO₂-C1-C5 alkyl, $-(CH_2)_m$ -CONH₂, $-(CH_2)_m$ -CONH-C1-C5 alkyl, or -CON-(C1-C5 alkyl)₂, or $(CH_2)_m$ -N-C1-C5 alkyl;~~

R^6 represents hydrogen, or C1-C5 alkyl, ~~cycloalkyl, or cycloalkyl-C1-C5 alkyl;~~

R^7 represents hydrogen; C1-C5 alkyl; C2-C5 alkenyl; or mono-, di- or tri-substituted phenyl or phenyl-C1-C5 alkyl, whereby the substituents ~~substituents~~ independently are C1-C5 alkyl, C1-C5 alkoxy, C2-C5 alkenyl or halogen; $-(CH_2)_m$ -OH; $-(CH_2)_m$ -O-C1-C5 alkyl; $-(CH_2)_m$ -CO₂H; $-(CH_2)_m$ -CO₂-C1-C5 alkyl; $-(CH_2)_m$ -CONH₂; $-(CH_2)_m$ -CONH-C1-C5 alkyl; or -CON-(C1-C5 alkyl)₂;

R^8 represents unsubstituted phenyl; ~~unsubstituted pyridyl, unsubstituted phenyl-C1-C5 alkyl, unsubstituted pyridyl-C1-C5 alkyl;~~ or mono-, di- or tri-substituted phenyl, ~~pyridyl, phenyl-C1-C5 alkyl or pyridyl-C1-C5 alkyl,~~ whereby the substituents independently are C1-C5 alkyl, C1-C5 alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy or halogen; and

R⁹ represents ~~C₁-C₅ alkyl, C₂-C₅ alkenyl, cycloalkyl, cycloalkyl C₁-C₅ alkyl, unsubstituted phenyl C₁-C₅ alkyl, or mono-, di- or tri-substituted phenyl or phenyl C₁-C₅ alkyl~~, whereby the substituents independently are C₁-C₅ alkyl, C₁-C₅ alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy or halogen;

or an optically pure ~~enantiomer~~enantiomers, ~~a mixture~~mixtures of enantiomers, ~~a racemate~~racemates, an optically pure ~~diastereoisomer~~diastereoisomers, a ~~mixture~~mixtures of diastereoisomers, a diastereoisomeric ~~racemate~~racemates, a mixture of diastereoisomeric racemates, or a meso ~~form~~forms, or a pharmaceutically acceptable ~~salts~~salts thereof.

2. (Currently Amended) The compound of formula (I) according to claim 1, wherein n is the integer 0, m is the integer 0, and X represents oxygen; or a pharmaceutically acceptable salt thereof.

3. (Currently Amended) The compound of formula (I) according to claim 1, wherein n is the integer 0, m is the integer 0, R⁵ represents methyl, R⁶ represents phenyl, and X represents oxygen; or a pharmaceutically acceptable salt thereof.

4. (Currently Amended) The compound according to claim 1 selected from the group consisting of:

1-[1-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-(1-phenyl-ethyl)-3-(2-propyl-phenyl)-urea;

~~3-Biphenyl-2-yl-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)]-1-[1-phenyl-ethyl]urea;~~

3-(2-Ethoxy-phenyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-(1-phenyl-ethyl)-urea;

3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-((S)-1-phenyl-ethyl)-urea;

3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-((R)-1-phenyl-ethyl)-urea;

3-(2-Ethoxy-phenyl)-1-(2-methoxy-(S)-1-phenyl-ethyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;

3-(2-Ethoxy-phenyl)-1-(2-methoxy-(R)-1-phenyl-ethyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;

(R)-2-{3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-ureido}-2-phenyl-acetamide;

(3-{1-[3-(Ethoxy-phenyl)-1-(1-phenyl-ethyl)-ureido]-ethyl}-2-oxo-2H-quinoxalin-1-yl)-acetic acid ethyl ester;

2-{3-[3-(2-Ethoxy-phenyl)-1-(1-phenyl-ethyl)-ureidomethyl]-2-oxo-2H-quinoxalin-1-yl}-acetamide;

1-Benzyl-3-(2-ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-urea;

1-Benzyl-3-(2-ethoxy-phenyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;

3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-1-(1-phenyl-ethyl)-urea;

(S)-3-(2-Ethoxy-phenyl)-1-(3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-(1-phenyl-ethyl)-urea;

~~1-(6-Chloro-pyridin-3-ylmethyl)-3-(2-ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea;~~

(S)-3-(2-Ethoxy-phenyl)-1-(2-methoxy-1-phenyl-ethyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;

(R)-3-(2-Ethoxy-phenyl)-1-(2-methoxy-1-phenyl-ethyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;

3-(2-Ethoxy-phenyl)-1-(2-hydroxy-(S)-1-phenyl-ethyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea;

3-(2-Ethoxy-phenyl)-1-(2-methoxy-(S)-1-phenyl-ethyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea;

3-(2-Ethoxy-phenyl)-1-(3-hydroxy-(S)-1-phenyl-propyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea;

~~3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-((S)-2-phenyl-propyl)-urea;~~

3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-[-1-(3-trifluoromethyl-phenyl)-ethyl]-urea; and

3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-[-1-(4-trifluoromethyl-phenyl)-ethyl]-urea; and

~~N-(2-Ethoxy-phenyl)-N'-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-N'-1-phenyl-ethyl-cyanoguanidine. or a pharmaceutically acceptable salt of such a compound.~~

5. (Previously Presented) A pharmaceutical composition comprising one or more compounds of claim 1, or a pharmaceutically acceptable salt thereof, and a carrier and/or adjuvant.

6.-11. (Cancelled)

12. (Previously Presented) A pharmaceutical composition comprising one or more compounds of claim 4, or a pharmaceutically acceptable salt thereof, and a carrier and/or adjuvant.

13. (Cancelled)

14. (Cancelled)